China pharma's candesartan hypertension product passes the quality and efficacy consistency evaluation of generic drugs

Haikou, china , aug. 9, 2023 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary hainan helpson medical & biotechnology co., ltd. (hereinafter referred to as "helpson") has received the "drug supplementary application approval notice" for its candesartan tablets by national medical products administration of china (hereinafter referred to as nmpa"), indicating that the company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs.
CPHI Ratings Summary
CPHI Quant Ranking